Literature DB >> 18308147

The medical treatment of inflammatory breast cancer.

Shaheenah Dawood1, Naoto T Ueno, Massimo Cristofanilli.   

Abstract

The multidisciplinary management of inflammatory breast cancer (IBC) includes neoadjuvant systemic chemotherapy, surgery, radiotherapy, and, in hormone receptor-positive disease, hormonal therapy. The use of induction chemotherapy with anthracyclines and taxanes somewhat improved the prognosis and local control of patients with IBC compared to local modalities alone. Improved understanding of the biological features of the disease has allowed for the development of targeted therapies (eg, trastuzumab and lapatinib) that are changing the outcome of this aggressive disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308147     DOI: 10.1053/j.seminoncol.2007.11.012

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  8 in total

1.  Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4.

Authors:  Fredika M Robertson; Ann-Marie Simeone; Anthony Lucci; John S McMurray; Sukhen Ghosh; Massimo Cristofanilli
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

2.  Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report.

Authors:  Yuji Yamashita; Yuko Tanaka; Seishi Kono; Meiko Nishimura; Toru Mukohara; Yukiko Morinaga; Shigeo Hara; Shintaro Takao
Journal:  Breast Care (Basel)       Date:  2017-02-28       Impact factor: 2.860

3.  Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients.

Authors:  Nabila Chaher; Hugo Arias-Pulido; Nadija Terki; Clifford Qualls; Kamel Bouzid; Claire Verschraegen; Anne Marie Wallace; Melanie Royce
Journal:  Breast Cancer Res Treat       Date:  2011-03-01       Impact factor: 4.872

4.  GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.

Authors:  Hugo Arias-Pulido; Melanie Royce; Yun Gong; Nancy Joste; Lesley Lomo; Sang-Joon Lee; Nabila Chaher; Claire Verschraegen; Juanita Lara; Eric R Prossnitz; Massimo Cristofanilli
Journal:  Breast Cancer Res Treat       Date:  2009-11-10       Impact factor: 4.872

5.  A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Authors:  Massimo Cristofanilli; Stephen R D Johnston; Alexey Manikhas; Henry L Gomez; Oleg Gladkov; Zhimin Shao; Sufia Safina; Kimberly L Blackwell; Ricardo H Alvarez; Stephen D Rubin; Sulabha Ranganathan; Suman Redhu; Maureen E Trudeau
Journal:  Breast Cancer Res Treat       Date:  2012-12-13       Impact factor: 4.872

6.  High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes.

Authors:  Ismahane Bekhouche; Pascal Finetti; José Adelaïde; Anthony Ferrari; Carole Tarpin; Emmanuelle Charafe-Jauffret; Colette Charpin; Gilles Houvenaeghel; Jocelyne Jacquemier; Ghislain Bidaut; Daniel Birnbaum; Patrice Viens; Max Chaffanet; François Bertucci
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

Review 7.  Nitrative and oxidative stress in toxicology and disease.

Authors:  Ruth A Roberts; Debra L Laskin; Charles V Smith; Fredika M Robertson; Erin M G Allen; Jonathan A Doorn; William Slikker
Journal:  Toxicol Sci       Date:  2009-08-05       Impact factor: 4.849

8.  HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.

Authors:  Preeti Putcha; Jiyang Yu; Ruth Rodriguez-Barrueco; Laura Saucedo-Cuevas; Patricia Villagrasa; Eva Murga-Penas; Steven N Quayle; Min Yang; Veronica Castro; David Llobet-Navas; Daniel Birnbaum; Pascal Finetti; Wendy A Woodward; François Bertucci; Mary L Alpaugh; Andrea Califano; Jose Silva
Journal:  Breast Cancer Res       Date:  2015-12-08       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.